Attached files

file filename
EX-99.1 - SERACARE LIFE SCIENCES INCv204166_ex99-1.htm
 
UNITED STATES SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
 
CURRENT REPORT
 
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

Date of Report (Date of Earliest Event Reported):    November 29, 2010
 
SeraCare Life Sciences, Inc.
 

 
(Exact name of registrant as specified in its charter)

Delaware
 
1-34105
 
33-0056054
         
(State or other jurisdiction
 
(Commission
 
(I.R.S. Employer
of incorporation)
 
File Number)
 
Identification No.)
  
       
37 Birch Street, Milford, Massachusetts
     
01757
         
(Address of principal executive offices)
  
 
  
(Zip Code)

Registrant's telephone number, including area code:    (508) 244-6400
 
Not Applicable
 

 
Former name or former address, if changed since last report
 
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
 
¨  Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
 
¨  Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
 
¨  Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
 
¨  Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

 
 

 

Item 2.02 
Results of Operations and Financial Condition.

On December 1, 2010, we issued a press release announcing our financial results for the quarter and fiscal year ended September 30, 2010.  A copy of the press release is attached hereto as exhibit 99.1 and incorporated by reference herein.

The information in this Item 2.02 and the press release attached hereto shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or the Exchange Act, or otherwise subject to the liabilities of that section, nor shall they be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, regardless of any general incorporation language in such filing.

Item 5.02  
Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

On November 29, 2010, William J. Smutny agreed to step down from his position as Vice President, Sales and Marketing.  It is expected that Mr. Smutny’s employment will end on or before December 31, 2010.  The terms of his severance package have not been finalized.

Item 9.01
Financial Statements and Exhibits.

(d) 
Exhibits

Exhibit No.
Description
99.1
Press Release issued by SeraCare Life Sciences, Inc. dated December 1, 2010

 
 

 
 
SIGNATURES
 
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

   
SeraCare Life Sciences, Inc.
  
       
December 1, 2010
 
By:
 
/s/ Gregory A. Gould
         
       
Name: Gregory A. Gould
       
Title: Chief Financial Officer, Treasurer and Secretary

 
 

 
 
Exhibit Index

Exhibit No.
 
Description
     
99.1
 
Press Release issued by SeraCare Life Sciences, Inc., dated December 1, 2010.